Prof. Dr. Sue Ann Costa Clemens is currently Professor of Pediatrics Infectious Diseases, Head of the Institute for Global Health University of Siena and Director Vaccine Group Oxford-Brazil, Visiting Professor in Global Health at Oxford University, Department of Paediatrics.
Sue Ann is one of the founders and the Program Director of Master Program in Vaccinology and Drug development at the University of Siena, since 2008. She is also Professor and Head of Clinical Department at Instituto Carlos Chagas, in Brazil. In addition, she is a Senior Advisor and consultant at the Bill and Melinda Gates Foundation, a position she has held since 2012. She has over 25 years of experience in the pharmaceutical industry (GSK, Merck, Novartis) in different roles and increasing responsibility in clinical development, medical affairs, regulatory affairs and medical governance. Sue Ann has headed vaccine development in Latin America for GSK, crucially contributing to world wide development of Rotavirus, HPV, pneumococcus, meningococcus, and pentavalent vaccines amongst others. She has also been in charge of Continuous Medical Education as a member of the International Group at the Educational Commission for Foreign Medical Graduates (ECFMG- Philadelphia, USA). In 2006, Sue Ann founded the clinical/medical consulting company GRID RIO and GRID Europe – “Global Research in Infectious Diseases” in partnership with GRID Switzerland in Zurich, GRID Germany in Munich and GRID Singapore in Singapore. Clients include prominent multinational pharmaceuticals as well as local private and public health companies. Since 2017, GRID Europe is proudly a sponsor of the Master in Vaccinology at the University of Siena. Currently for the Covid-19 activities she serves as Chairman Scientific Advisory Board Covid-19 MRI Gates, Member Scientific Advisory Board Covid-19 Curevac, Germany, Member Scientific Advisory Board Covid-19 Clover, China. National coordinator and Investigator for the Oxford Vaccine Study in Brazil and Principal Investigator for the Bill and Melinda Gates Foundation for Site Readiness grant, preparing 23 sites in 8 countries in Latin America for conducting Ph3 COVID -19 vaccine trials.